Paper Details

  1. Home
  2. Paper Details

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.

Author: AlbersFrank C, BarrosManuel, BourdinArnaud, BradfordEric S, BuhlRoland, GibsonPeter G, GilsonMartyn, HowarthPeter, KhatriSumita, LeighRichard, MasperoJorge, MooreWendy, OrtegaHector, PriceRobert G, YanceySteven W

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

An open-label extension study of 347 patients with severe eosinophilic asthma found that mepolizumab was safe and effective over an average of 3.5 years. The medication led to a significant reduction in exacerbation rates and improvements in asthma control.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Mepolizumab has demonstrated favorable safety and efficacy profiles in placebo-controlled trials of 12 months' duration or less; however, long-term data are lacking. OBJECTIVE: We sought to evaluate the long-term safety and efficacy of mepolizumab in patients with severe eosinophilic as...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.jaci.2018.09.033

データ提供：米国国立医学図書館（NLM）

Mepolizumab for Eosinophilic Asthma: A Long-Term Perspective

This research investigates the long-term safety and efficacy of mepolizumab, a medication used to treat severe eosinophilic asthma. Imagine a vast desert, where sandstorms can trigger intense coughing and wheezing, making it difficult to breathe. Eosinophilic asthma, like these sandstorms, can disrupt the respiratory system, causing inflammation and airway obstruction. This research, like a dedicated desert physician, seeks to understand the long-term impact of mepolizumab on managing this chronic condition.

Long-Term Safety and Efficacy: A Reliable Oasis in the Desert

The study demonstrates the favorable long-term safety and efficacy of mepolizumab in patients with eosinophilic asthma, highlighting its potential to improve asthma control and reduce exacerbations. The researchers meticulously analyzed data from a long-term extension study, evaluating the safety and effectiveness of mepolizumab over an extended period. Their findings provide reassurance regarding the safety of this medication and its potential to provide sustained relief for patients with eosinophilic asthma.

Navigating the Desert of Asthma: A Path to Improved Respiratory Health

This research underscores the importance of exploring long-term treatment options for severe eosinophilic asthma, ensuring that patients have access to effective and safe therapies. The study highlights the potential of mepolizumab to improve asthma control and reduce exacerbations, offering a promising avenue for managing this challenging respiratory condition.

Dr. Camel's Conclusion

This research provides valuable insights into the long-term safety and efficacy of mepolizumab for treating eosinophilic asthma. The study demonstrates the potential of this medication to improve asthma control and reduce exacerbations, offering hope for individuals facing this challenging respiratory condition.
Date :
  1. Date Completed 2020-05-11
  2. Date Revised 2020-05-11
Further Info :

Pubmed ID

30359681

DOI: Digital Object Identifier

10.1016/j.jaci.2018.09.033

Related Literature

Article Analysis
・Effects of mepolizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.